Rocuronium and sugammadex used effectively for electroconvulsive therapy in a patient with Brugada syndrome.

Abstract

We report the successful anesthetic management of a patient with Brugada syndrome who underwent electroconvulsive therapy to treat bipolar disorder. Suxamethonium and neostigmine were contraindicated to avoid the vagotonic effects that can precipitate ventricular fibrillation during anesthesia in patients with Brugada syndrome. The combination of 1.2 mg/kg rocuronium and 10 mg/kg sugammadex was effectively and safely used to induce and antagonize neuromuscular block for 8 consecutive electroconvulsive therapy sessions in this patient.

• Authors: Junpei Konishi, Takahiro Suzuki, Yuko Kondo, Miyako Baba, Setsuro Ogawa
• Journal: The journal of ECT (J ECT) Vol. 28 Issue 2 Pg. e21-2 (Jun 2012) ISSN: 1533-4112 [Electronic] United States
• PMID: 22622300 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)

Chemical References

• Androstanols
• Neuromuscular Nondepolarizing Agents
• gamma-Cyclodextrins
• Sugammadex
• Rocuronium

Topics

• Androstanols (adverse effects, antagonists & inhibitors)
• Anesthesia (methods)
• Anesthesia Recovery Period
• Bipolar Disorder (complications, psychology, therapy)
• Brugada Syndrome (complications)
• Bundle-Branch Block (complications)
• Electrocardiography
• Electroconvulsive Therapy (methods)
• Humans
• Male
• Middle Aged
• Neuromuscular Nondepolarizing Agents (adverse effects, antagonists & inhibitors)
• Rocuronium
• Sugammadex
• gamma-Cyclodextrins